SCHEMBL6071209

SCHEMBL6071209

Cc1ncccc1C(=O)Nc1ccc2[nH]c3c(ccc4cn[nH]c43)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 3/20 0.46
NPC1 O15118 6/20 0.45
RAB9A P51151 6/20 0.45
POLB P06746 1/20 0.45
JAK2 O60674 3/20 0.44
JAK1 P23458 2/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAOB P27338 1/20 0.43
IKBKB O14920 1/20 0.43
CHUK O15111 1/20 0.43
ICOSLG O75144 1/20 0.43
TYK2 P29597 1/20 0.43
CLK1 P49759 1/20 0.43
CLK2 P49760 1/20 0.43
DYRK1A Q13627 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
PI4KB Q9UBF8 1/20 0.43
ICOS Q9Y6W8 1/20 0.43
KDR P35968 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071127 0.82 NPC1 (0.51) NPC1RAB9APOLBJAK2JAK1
SCHEMBL6071391 0.77 ROCK2 (0.46) NPC1RAB9AJAK2HPGDSMN1; SMN2
SCHEMBL6071111 0.75 CNR1 (0.46) NPC1HPGD
SCHEMBL6071485 0.75 MAOB (0.56) NPC1RAB9APOLBSMN1; SMN2MAOB
SCHEMBL6071497 0.75 MAPK10 (0.54) VCPNPC1RAB9AHPGDKDR
SCHEMBL5583293 0.70 ACHE (0.46) NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL6449770 0.70 ROCK2 (0.35) NPC1RAB9APOLBJAK2MAOB
SCHEMBL6449766 0.70 ROCK2 (0.35) NPC1RAB9APOLBJAK2MAOB
SCHEMBL6071196 0.70 KMT2A (0.57) NPC1RAB9APOLBSMN1; SMN2CLK2
SCHEMBL6070986 0.69 RAB9A (0.46) NPC1RAB9APOLBSMN1; SMN2IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 VCP 1051/4885NPC1 2842/4885RAB9A 1100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.